Genvor appoints Donald Kalkofen CFO; $14K monthly cash + 575K options, going-concern clause in deferred pay

Genvor Inc

Donald Kalkofen appointed CFO effective May 18, 2026; 20+ years biotech/tech CFO experience including IPO at Alpha Cognition.
Cash compensation $6,250/month plus deferred $7,750/month; total $14,000/month from Jan 2027.
Options for 575,000 shares: 425,000 vest monthly over 12 months, 150,000 vest upon successful exchange listing.
Deferred comp due by Dec 31, 2026, but can be delayed if board determines going-concern risk.
Options forfeited if shareholder approval of equity plan not obtained by next annual meeting.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Donald Kalkofen

Chief Financial Officer

GNVR · Genvor Inc

Effective: 2026-05-18
Filed: May 21, 2026, 4:15 PM ET

appointed Donald Kalkofen as the Company’s Chief Financial Officer effective as of May 18, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Donald Kalkofen was appointed as Chief Financial Officer at Genvor Inc.

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

appointed Donald Kalkofen as the Company’s Chief Financial Officer effective as of May 18, 2026.

View on SEC.gov

Genvor Inc filing history →

Source: SEC EDGAR

accession 0001903596-26-000235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.